Bio Rad实验室 BIO 深 沪
等待开盘 03-26 09:30:00 美东时间
273.60
+1.480
+0.54%
华盛通- 最 高276.135
- 今 开273.92
- 成交量 25.24万股
- 最 低 269.10
- 昨 收 272.12
- 总市值 73.85亿
- 52周最高 343.12
- 市盈率 静 9.82
- 换手率 0.94%
- 52周最低 211.43
- 委 比 75.82%
- 总股本 2699.04万
- 历史最高 832.70
- 量 比 0.63
- 振 幅 2.59%
- 历史最低 84.02
- 每 手 1
- 风险率 31.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission
Insight Molecular Diagnostics Inc. (iMDx) has achieved several milestones for its GraftAssureDx™ test kit, including completing a three-site reproducibility study, collecting sufficient clinical samples, and receiving ISO 13485 certification. These steps advance their De Novo submission to the FDA and enable global regulatory submissions, targeting a $2 billion market for organ transplant rejection testing. The company is nearing completion of in...
03-03 13:00
Bio-Rad Updates Investors on Sartorius Strategic Investment Metrics
Bio-Rad Laboratories ( ($BIO) ) has shared an announcement. Bio-Rad Laboratorie...
02-20 06:20
BUZZ-U.S. STOCKS ON THE MOVE-Moderna, Mohawk
BUZZ-U.S. STOCKS ON THE MOVE-Moderna, Mohawk Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were muted on Friday, with communication services weighing as
02-13 23:38
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Jasper Therapeutics (NASDAQ:JSPR) stock rose 19.6% to $1.4 during Frid...
02-13 20:05
财报速睇 | Bio Rad实验室 2025财年Q4营收6.93亿美元，同比增长3.9%；归母净利润7.20亿美元，扭亏为盈
华盛资讯2月13日讯，Bio Rad实验室公布2025财年Q4业绩，公司Q4营收6.93亿美元，同比增长3.9%，归母净利润7.20亿美元，扭亏为盈。
02-13 06:17
Bio-Rad Laboratories shares are trading lower after the company reported mixed Q4 financial results and issued FY26 sales guidance below estimates.
Bio-Rad Laboratories shares are trading lower after the company reported mixed ...
02-13 05:50
Bio-Rad Laboratories Sees FY2026 Sales $2.596B-$2.622B vs $2.630B Est
Full-Year 2026 Financial OutlookBio-Rad is providing its financial outlook for the full-year 2026. The Company currently expects non-GAAP, currency neutral revenue growth of approximately 0.5 to 1.5 percent and an
02-13 05:19
Earnings Scheduled For February 12, 2026
Companies Reporting Before The Bell • Ambev (NYSE:ABEV) is estimated to report ...
02-12 19:11
iMDx Announces $26.0 Million Registered Direct Offering
<p>Insight Molecular Diagnostics Inc. announced the sale of 4.5 million shares at $5.75 each, raising approximately $26 million. The funds will support research and development, particularly expanding GraftAssure to heart transplant testing. The offering is under a shelf registration and Lake Street Capital Markets acted as agent. A significant shareholder, Bio-Rad, also participated. The company aims to use proceeds for general corporate purpose...
02-11 13:00
